🇺🇸 FDA
Patent

US 9975937

Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

granted A61KA61K38/00A61K38/1793

Quick answer

US patent 9975937 (Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia) held by THE UNITED SSTATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED SSTATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Grant date
Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/00, A61K38/1793, A61K38/2086, A61K45/06